Tech Company Financing Transactions
Viela Bio Funding Round
Viela Bio closed a $75 million Series B funding round on 6/18/2019. Investors included HBM Healthcare Investments, Barer & Son Capital and Cormorant Asset Management.
Transaction Overview
Company Name
Announced On
6/18/2019
Transaction Type
Venture Equity
Amount
$75,000,000
Round
Series B
Investors
Proceeds Purpose
This financing will support our upcoming regulatory milestone--the anticipated filing of our Biologics License Application with the U.S. FDA for our lead product candidate, inebilizumab, for the treatment of neuromyelitis optica spectrum disorder, or NMOSD.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
1 MedImmune Way 5th Floor
Gaithersburg, MD 20878
USA
Gaithersburg, MD 20878
USA
Phone
Undisclosed
Website
Email Address
Overview
Viela Bio (Nasdaq: VIE) is a biotechnology company pioneering and advancing treatments for severe inflammation and autoimmune diseases.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Bing Yao
Chief Medical Officer
Jorn Drappa
VP - Bus. Development
William Ragatz
VP - Bus. Development
Aaron Ren
VP - Finance
Mitchell Chan
VP - Human Resources
Kate Surdez
VP - Marketing
Maureen Menacher
VP - Operations
Yang Wang
VP - Regulatory Affairs
Soraya Madani
Browse more venture capital transactions:
Prev: 6/18/2019: Clockwise venture capital transaction
Next: 6/18/2019: IronScales venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. VC transactions on this site are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs